280 related articles for article (PubMed ID: 36839241)
1. The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.
Haas M; Lein A; Fuereder T; Brkic FF; Schnoell J; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839241
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
Miyamoto N; Takenaka Y; Sudo T; Eguchi H; Tanaka H; Fukusumi T; Takemoto N; Suzuki M; Inohara H
Acta Otolaryngol; 2023 Oct; 143(10):925-930. PubMed ID: 38059478
[TBL] [Abstract][Full Text] [Related]
3. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
4. Does the geriatric nutrition risk index predict the prognosis of patients with oral squamous cell carcinoma?
Yamagata K; Fukuzawa S; Uchida F; Terada K; Ishibashi-Kanno N; Bukawa H
Br J Oral Maxillofac Surg; 2022 May; 60(4):475-481. PubMed ID: 35086741
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
[TBL] [Abstract][Full Text] [Related]
6. The Geriatric Nutritional Risk Index as a Prognostic Factor in Patients with Advanced Head and Neck Cancer.
Nakayama M; Gosho M; Adachi M; Ii R; Matsumoto S; Miyamoto H; Hirose Y; Nishimura B; Tanaka S; Wada T; Tabuchi K
Laryngoscope; 2021 Jan; 131(1):E151-E156. PubMed ID: 32083731
[TBL] [Abstract][Full Text] [Related]
7. Geriatric nutritional risk index predicts the prognosis of gastric cancer patients treated with immune checkpoint inhibitors.
Liu B; Zhang L
Medicine (Baltimore); 2024 Apr; 103(17):e37863. PubMed ID: 38669385
[TBL] [Abstract][Full Text] [Related]
8. The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin.
Fujiwara Y; Sato Y; Hayashi N; Fukuda N; Wang X; Nakano K; Ohmoto A; Urasaki T; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takahashi S
J Geriatr Oncol; 2023 Jun; 14(5):101523. PubMed ID: 37229881
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the Nutritional Risk Index, Geriatric Nutritional Risk Index, BMI, and GLIM-Defined Malnutrition in Predicting Survival of Patients with Head and Neck Cancer Patients Qualified for Home Enteral Nutrition.
Przekop Z; Szostak-Węgierek D; Milewska M; Panczyk M; Zaczek Z; Sobocki J
Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334925
[TBL] [Abstract][Full Text] [Related]
10. Geriatric nutritional risk index as a nutritional and survival risk assessment tool in stable outpatients with systolic heart failure.
Sargento L; Vicente Simões A; Rodrigues J; Longo S; Lousada N; Palma Dos Reis R
Nutr Metab Cardiovasc Dis; 2017 May; 27(5):430-437. PubMed ID: 28438373
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of preoperative Geriatric Nutritional Risk Index in oral squamous cell carcinoma.
Ito Y; Abe A; Hayashi H; Momokita M; Furuta H
Oral Dis; 2023 Jul; 29(5):2076-2085. PubMed ID: 35582815
[TBL] [Abstract][Full Text] [Related]
12. Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors.
Pan C; Wu QV; Voutsinas J; Houlton JJ; Barber B; Rizvi ZH; Marchiano E; Futran N; Laramore GE; Liao JJ; Parvathaneni U; Martins RG; Fromm JR; Rodriguez CP
Cancer Med; 2023 Apr; 12(8):9384-9391. PubMed ID: 36806947
[TBL] [Abstract][Full Text] [Related]
13. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of the pretreatment geriatric nutritional risk index for predicting severe adverse events in patients with head and neck cancer treated with chemoradiotherapy.
Nakayama M; Ohnishi K; Adachi M; Ii R; Matsumoto S; Nakamura M; Miyamoto H; Hirose Y; Nishimura B; Tanaka S; Wada T; Tabuchi K
Auris Nasus Larynx; 2022 Apr; 49(2):279-285. PubMed ID: 34509306
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
[TBL] [Abstract][Full Text] [Related]
16. The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors.
Liu C; Zhao H; Wang P; Guo Z; Qu Z
Int Immunopharmacol; 2023 Oct; 123():110704. PubMed ID: 37506504
[TBL] [Abstract][Full Text] [Related]
17. Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma.
Kanemasa Y; Shimoyama T; Sasaki Y; Hishima T; Omuro Y
Ann Hematol; 2018 Jun; 97(6):999-1007. PubMed ID: 29427185
[TBL] [Abstract][Full Text] [Related]
18. A Novel Prognostic Model Using Pan-Immune-Inflammation Value and Programmed Death Ligand 1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Retrospective Multicenter Analysis.
Lien MY; Hwang TZ; Wang CC; Hsieh CY; Yang CC; Wang CC; Lien CF; Shih YC; Yeh SA; Hsieh MC
Target Oncol; 2024 Jan; 19(1):71-79. PubMed ID: 38041732
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
[No Abstract] [Full Text] [Related]
20. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients.
Willemsen ACH; De Moor N; Van Dessel J; Baijens LWJ; Bila M; Hauben E; van den Hout MFCM; Vander Poorten V; Hoeben A; Clement PM; Schols AMWJ
Cancer Med; 2023 Apr; 12(7):7699-7712. PubMed ID: 36484469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
